Skip to main content

Table 2 Adverse events during radiotherapy

From: First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer

 

Total

G1

G2

G3

General

 

15(42%)

 Fatigue

14(39%)

13(36%)

1(3%)

0

 Radiation dermatitis

4(11%)

3(8%)

1(3%)

0

Hematologic

 

25(69%)

 Leucopenia

15(42%)

9(25%)

6(17%)

0

 Neutropenia

9(25%)

7(19%)

2(6%)

0

 Anemia

18(50%)

12(33%)

6(17%)

0

 Thrombocytopenia

8(22%)

3(8%)

3(8%)

2(6%)

Respiratory

 

9(25%)

 Radiation pneumonitis

3(8%)

1(3%)

2(6%)

0

 Immune-related pneumonitis

 before RT

4(11%)

4(11%)

0

0

 Immune-related pneumonitis

 after RT

1(3%)

0

1(3%)

0

 Pulmonary fibrosis

1(3%)

   

Gastrointestinal

 

25(69%)

 Radition esophagitis

18(50%)

15(42%)

3(8%)

0

 Nausea

11(31%)

11(31%)

0

0

 Constipation

2(6%)

2(6%)

0

0

 Elevated transaminase

4(11%)

4(11%)

0

0

Others

 

5(14%)

 Pleural reactive pleural

 effusion

1(3%)

1(3%)

0

0

 Elevated urinary protein

1(3%)

1(3%)

0

0

 Allergic reaction before RT

2(6%)

2(6%)

0

0

  1. RT: radiotherapy; G1: grade 1; G2: grade 2; G3: grade 3